FAQs (Frequently Asked Questions)
Explore the FAQs (Frequently Asked Questions) regarding the Liquid Biopsy for Precision Oncology East Coast Summit:
What is the 4th Liquid Biopsy for Precision Oncology East Coast Summit?
Starting as the Liquid Biopsy Early Detection and Surveillance Summit, this conference created a focused space for deep discussion in a niche, hyper-focused setting. Delivering core insights including MRD, circulating tumour DNA (ctDNA) analysis, pre-analytical validation, biomarker validation, clinical validation, Circulating Tumor Cells (CTCs), microRNAs, cell-free DNA (cfDNA), and more.
As the field evolved, however, this narrow focus unfortunately neglected some of the most critical conversations: regulation, reimbursement, commercialization, plus the role of liquid biopsies in ADCs, RAS-mutant targeted therapies, personalized cancer vaccines, rare disease, and haematology.
Now returning as the 4th Liquid Biopsy for Precision Oncology East Coast Summit, we’re excited to deliver an end-to-end view of liquid biopsy use in clinical trials, which will feature insights from large pharma, innovative biotech's, and key consortia across a content-packed, 2-day Summit.
Why Are Liquid Biopsies Important?
Liquid biopsies are becoming one of the most exciting tools in biopharma’s arsenal, offering non-invasive testing across a range of cancers. From improving diagnosis and prognosis to predicting recurrence and enabling ongoing patient monitoring, liquid biopsies – often through simple blood draws – support better decision-making throughout clinical trials and into routine care.
Is It Really *Free to Attend for Biopharma?
Yes! This really is a free-to-attend Summit for drug developers** who are not actively selling services or platforms to others at industry events. You can review the full terms and conditions here, or contact us directly at info@hansonwade.com to confirm your eligibility for a *complimentary pass – 90% of our audience qualifies!
Why Is It *Free to Attend for Biopharma?
We are committed to ensuring that this critical area, growing at unprecedented rates and with the potential to truly revolutionize oncology, has a platform to unite, collaborate, and drive progress. By removing barriers for attendance, we aim to bring together the brightest minds in biopharma to share insights, align on challenges, and accelerate the clinical adoption of liquid biopsy technologies that could transform patient care.
The 4th Liquid Biopsy for Precision Oncology East Coast Summit offers tailored partnership opportunities for solution providers looking to showcase their expertise and gain visibility with our highly specialized, senior-level audience.
Reach out to us here to explore how we can support your goals in more detail.
Who Partners with the 4th Liquid Biopsy for Precision Oncology East Coast Summit?
We partner with innovative solution providers across diagnostics, technology, and services who are driving advancements in liquid biopsy, ranging from assay development and biomarker discovery to AI-powered analysis, sample preparation, and regulatory support.
Our partners are looking to showcase their expertise, build meaningful connections, and position themselves in front of a senior, engaged biopharma audience focused on the clinical adoption of liquid biopsies and precision oncology breakthroughs.
Who are the Expert Speakers?
Leading Pharma
Joshua Levin, Director, Precision Medicine & Digital Health
GlaxoSmithKline
Emily Chan, Executive Director – Oncology Global Development
Amgen
Raluca Predoiu, Director - Companion Diagnostic Strategy Lead
AbbVie
Innovative Biotech
Qing Li, Director - Pathology, Clinical Development & Oncology
Moderna
John Boyce, Co-Founder & Managing Partner
BrickBio
Haifa Ghandour, Associate Director, Diagnostics Strategy & Development
Alexion Pharma
Leading Experts & KOL’s
Carolina Reduzzi, Associate Professor & Director of Liquid Biopsies
Weill Cornell Medicine
David Wurtman, Chief Business Officer
Geneos Therapeutics
Lauren Houghtalin, Director, Disease State, Technical Sales
BioIVT